| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 58,766 | 62,472 | 57,336 | 37,428 |
| Cost of product and other revenue | 9,383 | 9,919 | 7,625 | 5,150 |
| Amortization of intangible asset | 0 | 0 | - | 9,011 |
| Total cost of goods sold | 9,383 | 9,919 | 7,625 | 14,161 |
| Research and development | 14,944 | 11,013 | 9,754 | 8,487 |
| Selling, general and administrative | 29,094 | 26,555 | 25,742 | 26,516 |
| License | 896 | 896 | 701 | 769 |
| Restructuring | 0 | 0 | - | - |
| Total operating expenses | 44,934 | 38,464 | 36,197 | 35,772 |
| Income (loss) from operations | 4,449 | 14,089 | 13,514 | -12,505 |
| Interest expense | -4,748 | -6,834 | -7,770 | -6,661 |
| Other income (expense) | -10 | -28 | 213 | -17 |
| Change in fair value of warrant liability | -1,464 | 6,980 | -155 | 856 |
| Loss on extinguishment of debt | 0 | 0 | - | - |
| Income (loss) before income taxes | 1,155 | 247 | 6,112 | -20,039 |
| Income tax expense | 615 | - | - | - |
| Net income (loss) | 540 | 247 | 6,112 | - |
| Net loss, diluted | - | - | - | -20,039 |
| Comprehensive income (loss) | 540 | 247 | 6,112 | - |
| Basic (in dollars per share) | 0 | 0 | 0.03 | -0.1 |
| Basic (in shares) | 264,786,432 | 262,565,500 | 235,497,720 | 210,348,459 |
| Diluted (in dollars per share) | 0 | 0 | 0.03 | -0.1 |
| Diluted (in shares) | 274,372,722 | 271,104,020 | 241,602,853 | 210,348,459 |
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)